Research Article
Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells
Table 1
Patient’s characteristics at baseline (
patients).
| | Variables | |
| | Prior SLE medication history | | | Prednisone use | 69 (100%) | | Prednisone daily dose/mg, median (range) | 20 (5-500) | | CYC use | 47 (68.1%) | | MMF use | 19 (27.5%) | | HCQ use | 31 (44.9%) | | LEF use | 14 (20.3%) | | Clinical and biological symptoms | | | Fever | 25 (36.2%) | | Rash | 44 (63.8%) | | Photosensitivity | 33 (47.8%) | | Oral ulcers | 12 (17.4%) | | Arthralgia/arthritis | 49 (71.0%) | | Serositis | 17 (24.6%) | | Vasculitis | 14 (20.3%) | | Alopecia | 19 (27.5%) | | Renal disorder | 64 (92.8%) | | Active lupus nephritis | 63 (91.3%) | | Neurologic disorder | 5 (7.3%) | | Cardiorespiratory disorder | 19 (27.5%) | | Hematological disorder | 32 (46.4%) | | Immunologic disorder | 40 (58.0%) | | Antinuclear antibodies | 54 (78.3%) | | Anti-dsDNA | 27 (39.1%) | | Anti-Sm | 21 (30.4%) | | Anti-SSA | 17 (24.6%) | | Anti-SSB | 6 (8.7%) | | Low complement | 30 (43.5%) | | CYC induction | 42 (60.9%) | | Allo-MSC transplantation | | | Sources of MSCs (BM/UC) | 18/51 | | Second MSCs | 24 (34.8%) | | SLEDAI score at baseline, median (range) | 13 (8-34) | | CR during 1 year | 16 (23.2%) | | LDA during 1 year | 40 (58.0%) |
|
|
SLE: systemic lupus erythematosus; Anti-dsDNA: anti-double-stranded DNA antibody; Allo-MSCs: allogenic mesenchymal stem cells; BM: bone marrow-derived; UC: umbilical cord-derived; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; CYC: cyclophosphamide; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine; LEF: leflunomide; CR: clinical remission; LDA: low disease activity.
|
